Panbela Receives Approvals To Open Trial Sites In Spain, France And Italy For ASPIRE Trial Studying Ivospemin In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of
